Botulinum Toxin A Injections
(Botox®, Vistabel®, Dysport®, Azzalure®, Bocouture®...)
Facial wrinkles occur when we make repeated facial expression involving muscle contraction. With age, these wrinkles deepen, particularly forehead wrinkles, frown lines and crow’s feet.
Type A botulinum toxin is a neurotoxin produced by a bacteria and works by blocking nerve pulses.
Evidence provided by scientific studies has confirmed the safety and efficacy of type A botulinum toxin, when isolated and purified in controlled conditions, for use in aesthetic medicine. It is currently being sold commercially in Europe by three companies under the brand names Vistabel® (or Botox®), Azzalure® (or Dysport®) and Bocouture® (or Xeomin®).
Very low doses of the product are injected directly into the muscle, so natural expression is maintained.
The injection technique requires precision, skill and expert knowledge of muscular balance. The practitioner administers several tiny injections into the skin or muscles of the area to be treated with a very fine needle. Slight pain on injection and occasionally bruising, tenderness or redness may be experienced, but will rapidly subside.
The results of the procedure will be visible in the days following the injection and should reach maximum effect 1 to 2 weeks after the treatment. These results will last for between 4 and 6 months.
The astonishing results obtained by botulinum toxin make it a precious weapon in the battle against aging. It helps regain a youthful, fresh and radiant appearance, without losing natural expression or resorting to surgery. It can benefit both men and women, as soon as the first signs of aging appear.
Vistabel® and Azzalure® are registered trademarks marketed by the pharmaceutical companies Allergan and Galderma. In France, they were granted a marketing authorisation by the national health authorities.
Bocouture®, commercialised by Merz, is currently being registered with the European Health Authorities.